BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 31661302)

  • 1. Pulmonary Outcomes Associated with Long-Term Azithromycin Therapy in Cystic Fibrosis.
    Nichols DP; Odem-Davis K; Cogen JD; Goss CH; Ren CL; Skalland M; Somayaji R; Heltshe SL
    Am J Respir Crit Care Med; 2020 Feb; 201(4):430-437. PubMed ID: 31661302
    [No Abstract]   [Full Text] [Related]  

  • 2. Azithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosis.
    Nick JA; Moskowitz SM; Chmiel JF; Forssén AV; Kim SH; Saavedra MT; Saiman L; Taylor-Cousar JL; Nichols DP
    Ann Am Thorac Soc; 2014 Mar; 11(3):342-50. PubMed ID: 24476418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral Azithromycin and Response to Pulmonary Exacerbations Treated with Intravenous Tobramycin in Children with Cystic Fibrosis.
    Klingel M; Stanojevic S; Tullis E; Ratjen F; Waters V
    Ann Am Thorac Soc; 2019 Jul; 16(7):861-867. PubMed ID: 30874447
    [No Abstract]   [Full Text] [Related]  

  • 4. Oral Azithromycin Use and the Recovery of Lung Function from Pulmonary Exacerbations Treated with Intravenous Tobramycin or Colistimethate in Adults with Cystic Fibrosis.
    Somayaji R; Russell R; Cogen JD; Goss CH; Nick SE; Saavedra MT; Taylor-Cousar JL; Nick JA; Nichols DP
    Ann Am Thorac Soc; 2019 Jul; 16(7):853-860. PubMed ID: 30840835
    [No Abstract]   [Full Text] [Related]  

  • 5. Inhaled aztreonam lysine versus inhaled tobramycin in cystic fibrosis. An economic evaluation.
    Schechter MS; Trueman D; Farquharson R; Higuchi K; Daines CL
    Ann Am Thorac Soc; 2015 Jul; 12(7):1030-8. PubMed ID: 26053185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of azithromycin on the clinical and antimicrobial effectiveness of tobramycin in the treatment of cystic fibrosis.
    Nichols DP; Happoldt CL; Bratcher PE; Caceres SM; Chmiel JF; Malcolm KC; Saavedra MT; Saiman L; Taylor-Cousar JL; Nick JA
    J Cyst Fibros; 2017 May; 16(3):358-366. PubMed ID: 28025037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic Azithromycin Use in Cystic Fibrosis and Risk of Treatment-Emergent Respiratory Pathogens.
    Cogen JD; Onchiri F; Emerson J; Gibson RL; Hoffman LR; Nichols DP; Rosenfeld M
    Ann Am Thorac Soc; 2018 Jun; 15(6):702-709. PubMed ID: 29474110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhaled tobramycin effectively reduces FEV1 decline in cystic fibrosis. An instrumental variables analysis.
    VanDyke RD; McPhail GL; Huang B; Fenchel MC; Amin RS; Carle AC; Chini BA; Seid M
    Ann Am Thorac Soc; 2013 Jun; 10(3):205-12. PubMed ID: 23802816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis.
    McCoy KS; Quittner AL; Oermann CM; Gibson RL; Retsch-Bogart GZ; Montgomery AB
    Am J Respir Crit Care Med; 2008 Nov; 178(9):921-8. PubMed ID: 18658109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial.
    Mayer-Hamblett N; Retsch-Bogart G; Kloster M; Accurso F; Rosenfeld M; Albers G; Black P; Brown P; Cairns A; Davis SD; Graff GR; Kerby GS; Orenstein D; Buckingham R; Ramsey BW;
    Am J Respir Crit Care Med; 2018 Nov; 198(9):1177-1187. PubMed ID: 29890086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Inhaled Antibiotics for the Treatment of Chronic Pseudomonas aeruginosa Lung Infection in Patients With Cystic Fibrosis: Systematic Literature Review and Network Meta-analysis.
    Elborn JS; Vataire AL; Fukushima A; Aballea S; Khemiri A; Moore C; Medic G; Hemels ME
    Clin Ther; 2016 Oct; 38(10):2204-2226. PubMed ID: 27692977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testing the effects of combining azithromycin with inhaled tobramycin for
    Nichols DP; Singh PK; Baines A; Caverly LJ; Chmiel JF; GIbson RL; Lascano J; Morgan SJ; Retsch-Bogart G; Saiman L; Sadeghi H; Billings JL; Heltshe SL; Kirby S; Kong A; Nick JA; Mayer-Hamblett N;
    Thorax; 2022 Jun; 77(6):581-588. PubMed ID: 34706982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.
    Saiman L; Anstead M; Mayer-Hamblett N; Lands LC; Kloster M; Hocevar-Trnka J; Goss CH; Rose LM; Burns JL; Marshall BC; Ratjen F;
    JAMA; 2010 May; 303(17):1707-15. PubMed ID: 20442386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantifying Long-Term Changes in Lung Function and Exacerbations after Initiation of Azithromycin in Cystic Fibrosis.
    Denis A; Touzet S; Diabaté L; Durieu I; Lemonnier L; Poupon-Bourdy S; Iwaz J; Reynaud Q; Rabilloud M
    Ann Am Thorac Soc; 2020 Feb; 17(2):195-201. PubMed ID: 31604024
    [No Abstract]   [Full Text] [Related]  

  • 15.
    Keating CL; Zuckerman JB; Singh PK; McKevitt M; Gurtovaya O; Bresnik M; Marshall BC; Saiman L
    Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33318007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis.
    Saiman L; Mayer-Hamblett N; Campbell P; Marshall BC;
    Am J Respir Crit Care Med; 2005 Oct; 172(8):1008-12. PubMed ID: 16040785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution.
    Sawicki GS; Signorovitch JE; Zhang J; Latremouille-Viau D; von Wartburg M; Wu EQ; Shi L
    Pediatr Pulmonol; 2012 Jan; 47(1):44-52. PubMed ID: 21815282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial.
    Assael BM; Pressler T; Bilton D; Fayon M; Fischer R; Chiron R; LaRosa M; Knoop C; McElvaney N; Lewis SA; Bresnik M; Montgomery AB; Oermann CM;
    J Cyst Fibros; 2013 Mar; 12(2):130-40. PubMed ID: 22985692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
    Ramsey BW; Pepe MS; Quan JM; Otto KL; Montgomery AB; Williams-Warren J; Vasiljev-K M; Borowitz D; Bowman CM; Marshall BC; Marshall S; Smith AL
    N Engl J Med; 1999 Jan; 340(1):23-30. PubMed ID: 9878641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Concomitant Azithromycin and Tobramycin Use on Cystic Fibrosis Pulmonary Exacerbation Treatment.
    Cogen JD; Faino AV; Onchiri F; Gibson RL; Hoffman LR; Kronman MP; Rosenfeld M; Nichols DP
    Ann Am Thorac Soc; 2021 Feb; 18(2):266-272. PubMed ID: 32810412
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.